By Associate Professor Anthony Michael Joshua

Book Chapters

Covelli AM; Joshua AM; Lipa JE; Butler MO; Snell L; Sun A; Wright FC, 2020, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 333 - 343, http://dx.doi.org/10.1007/978-3-030-48363-0_17

Lim DW; Yin L; Racz JM; Joshua AM; Abadir WWK; Butler MO; Lipa JE; Sun A; Wright FC, 2020, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 383 - 393, http://dx.doi.org/10.1007/978-3-030-48363-0_19

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 189 - 196, http://dx.doi.org/10.1007/978-3-319-26276-5_14

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 225 - 232, http://dx.doi.org/10.1007/978-3-319-26276-5_17

Journal articles

Chambers CR; Watakul S; Schofield P; Howell AE; Zhu J; Tran AMH; Kuepper N; Reed DA; Murphy KJ; Channon LM; Pereira BA; Tyma VM; Lee V; Trpceski M; Henry J; Melenec P; Abdulkhalek L; Nobis M; Metcalf XL; Ritchie S; Cadell A; Stoehr J; Magenau A; Chacon-Fajardo D; Chitty JL; O’Connell S; Zaratzian A; Tayao M; Silva AD; Lyons RJ; Goldstein LD; Dale A; Rookyard A; Connolly A; Crossett B; Tran YTH; Kaltzis P; Vennin C; Dinevska M; Croucher DR; Samra J; Mittal A; Weatheritt RJ; Philp A; Monte-Nieto GD; Zhang L; Enriquez RF; Cox TR; Shi YCC; Pinese M; Waddell N; Sim HW; Chtanova T; Wang Y; Joshua AM; Chantrill L; Jeffry Evans TR; Gill AJ; Morton JP; Pajic M; Christ D; Herzog H; Timpson P; Herrmann D, 2025, 'Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis', Science Advances, 11, http://dx.doi.org/10.1126/sciadv.adq4416

Conduit C; Inderjeeth AJ; Allen R; Martin AJ; Parulekar W; Mulroe E; McJannett M; Zielinski RR; Thomson A; Tan TH; Sandhu SK; Reaume MN; Pook DW; North SA; Marx GM; Joshua A; Horvath L; McDermott R; Chowdhury S; Chi KN; Zhang AY; Stockler MR; Davis ID; Sweeney CJ, 2025, 'Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)', Future oncology (London, England), 21, pp. 627 - 636, http://dx.doi.org/10.1080/14796694.2024.2440277

Jafri Z; Zhang J; O'Meara CH; Joshua AM; Parish CR; Khachigian LM, 2025, 'Interplay between CD28 and PD-1 in T cell immunotherapy', Vascular Pharmacology, 158, http://dx.doi.org/10.1016/j.vph.2024.107461

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Kumar ASR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; McJannett M; Thomas H; Langford A; Hofman MS; Martin AJ; Davis ID; Stockler MR; Subramaniam S; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Gedye C; Rutherford NK; Ravi Kumar AS; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Butler P; Zhang AY; Thomas H; Langford A; Hofman MS; Martin AJ; Davis ID; Stockler MR; Zebic D; Mak B; Tankard N; Rana N; Cusick T; Thompson J; Oakes S; Niu C; Thein T; Ford K; Ristevski N; Yip S; Bills M, 2025, 'Overall survival and quality of life with [¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial', The Lancet Oncology, 26, pp. 291 - 299, http://dx.doi.org/10.1016/S1470-2045(25)00009-9

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218

Crumbaker M; Krieger L; Pook DW; Davis ID; Fontela A; Oldmeadow C; Hurwitz J; Inderjeeth AJ; Dhillon HM; Downton T; Marx GM; Shekar S; Antonarakis ES; Denmeade SR; Anton A; Tan TH; Sharma S; Goh JC; Horvath L; Joshua AM, 2025, 'Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.tps298

Scheinberg T; Kench JG; Ferguson P; Sutherland S; Stockler MR; Mahon KL; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Marx GM; Davis ID; Sengupta S; Leslie S; Centenera MM; Butler L; Horvath L, 2025, 'LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.', Journal of Clinical Oncology, 43, pp. 392 - 392, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.392

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Sandhu S; Zhang AY; Hofman MS; Thomas H; Martin AJ; Davis ID; Stockler MR, 2025, 'Overall survival and quality of life with [ ¹⁷⁷ Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).', Journal of Clinical Oncology, 43, pp. 17 - 17, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.17

Lin KL; Shekar S; Crumbaker M; Joshua AM, 2025, 'Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men', New England Journal of Medicine, 392, pp. 202 - 203, http://dx.doi.org/10.1056/NEJMc2412361

Liu J; Farrow M; Seymour L; Desai J; Loong HH; Ivy P; Koyoma T; Cook N; Blagden S; Garralda E; Massard C; Tolcher AW; Adashek JJ; Zhang L; Zhao S; Shen L; Kurzrock R; El-Deiry WS; Subbiah V; Joshua AM, 2025, 'Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials', Journal of Clinical Oncology, http://dx.doi.org/10.1200/JCO-24-01534

Pham JP; Staeger R; Joshua AM; Liu J; da Silva IP; Dummer R; Goldinger SM, 2025, 'An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115121

Rollin SPG; Lawrence MG; Joshua AM; Selth LA, 2025, 'Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer', Endocrine-Related Cancer, 32, http://dx.doi.org/10.1530/ERC-24-0208

Dimitriou F; Orloff MM; Koch Hein EC; Cheng PF; Hughes IF; Simeone E; Montazeri K; Grover P; Mehmi I; Gerard CL; Gaudy-Marqueste C; Grob JJ; Michielin O; Hamid O; Long GV; Sullivan R; Kapiteijn E; Johnson DB; Ascierto PA; Joshua AM; Carvajal RD; Butler MO; Hassel JC; Dummer R, 2025, 'Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115161

El-Deiry WS; Bresson C; Wunder F; Carneiro BA; Dizon DS; Warner JL; Graff SL; Azzoli CG; Wong ET; Cheng L; Mani SA; Safran HP; Williams C; Meissner T; Solomon B; Rubin E; Porgador A; Berchem G; Saintigny P; Onn A; Bar J; Berger R; Gantenbein M; Chen Z; de Pádua Souza C; Reis RMV; Sekacheva M; Cervantes A; Dahut WL; Annunziata CM; Gober K; Musallam KM; Al-Shamsi HO; Abu-Gheida I; Salazar R; Limaye S; Aref AT; Reddel RR; Al Homsi MU; Rouf A; Dermime S; Al Suwaidi J; Vlad C; Buiga R; Al Omari A; Abdel-Razeq H; Oñate-Ocaña LF; Nielsen FC; Graham L; Rueter J; Joshua AM; Girda E; Libutti S; Riedlinger G; Salem ME; Farhangfar CJ; Mesa RA; Faltas BM; Elemento O; Pramesh CS; Sengar M; Aoyama S; Ikeda S; Berindan-Neagoe I; Gaddipati H; Kulkarni M; Auzias E; Gerogianni M; Wolikow N; Istolainen S; Schlafrig P; Frankel NZ; Ferraro AR; Palma J; Gimenez AP; Hernando-Calvo A; Felip E; Tsimberidou AM; Herbst RS; Tabernero J; Schilsky RL; Liu J; Lussier Y; Raynaud J; Batist G; Magidi S; Kurzrock R, 2025, 'Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients', Oncotarget, 16, pp. 140 - 162, http://dx.doi.org/10.18632/oncotarget.28703

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [¹⁷⁷Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', The Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

O'Day RF; Conway RM; Lim LA; Giblin M; Cherepanoff S; Joshua A; McKay D; McKenzie JD; Fog LS; Holly P; Shackleton M; Kee D; Philips C; McKelvie P; Bhikoo R; Hadden P; Negretti GS; Sagoo MS; Damato BE; Sia D; McGrath L; Glasson W; Isaacs T; Gillies M; Barthelmes D, 2024, 'The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma', Canadian Journal of Ophthalmology, 59, pp. e525 - e533, http://dx.doi.org/10.1016/j.jcjo.2024.05.006

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of ⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on ⁶⁸Ga-PSMA-11 PET/CT', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF, 2024, 'Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity (Cancer Chemotherapy and Pharmacology, (2017), 79, 5, (959-969), 10.1007/s00280-017-3298-5)', Cancer Chemotherapy and Pharmacology, 94, pp. 485 - 486, http://dx.doi.org/10.1007/s00280-023-04636-2

Yu EY; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PC; Piulats JM; Berry W; Emmenegger U; Mourey L; Joshua AM; Mar N; Appleman LJ; Conter HJ; Gravis G; Li XT; Schloss C; Poehlein C; de Bono JS, 2024, 'Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.', Eur Urol Oncol, http://dx.doi.org/10.1016/j.euo.2024.05.013

Fleshner NE; Bernardino RM; Lajkosz K; Saad F; Izawa J; Drachenberg D; Saranchuk JW; Tanguay S; Rendon RA; Leveridge M; Shayegan B; Fairey A; Cockburn JG; Berlin D; Hamilton RJ; Sildva T; Breau RH; Richard PO; Klotz L; Joshua AM, 2024, 'A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.', Journal of Clinical Oncology, 42, pp. LBA5002 - LBA5002, http://dx.doi.org/10.1200/jco.2024.42.17_suppl.lba5002

Joshua AM; O'day R; Glasson W; Sia D; McGrath L; Ameratunga M; Cosman R; Cherepanoff S; O'Quigley M; Beaupre DM; Conway M; Lim L-A; McKenzie J; McKay D; Shackleton MJ; Fung A; Isaacs T; Yousif J; Brooks C; Psaroulis T, 2024, 'A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.', Journal of Clinical Oncology, 42, pp. 9510 - 9510, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.9510

Kwan EM; Hofman MS; Ng SWS; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee ST; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Tolmeijer SH; Azad A; Davis ID; Wyatt AW, 2024, 'Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', Journal of Clinical Oncology, 42, pp. 5055 - 5055, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5055

Liu JJ; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Aktas BY; Cosman R; Chwialkowska D; Paull J; Main NJ; Jean-Francois BM; Le Meur J; Edmondson SR; Cook N, 2024, 'Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.', Journal of Clinical Oncology, 42, pp. 3014 - 3014, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3014

Spicer JF; Pinato DJ; Forster M; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu JJ; Cosman R; Main NJ; Le Meur J; Paull J; Edmondson SR; Jones RH, 2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).', Journal of Clinical Oncology, 42, pp. 3004 - 3004, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3004

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau HT; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; de Spéville BD, 2024, 'First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study', Cancer Research Communications, 4, pp. 1609 - 1619, http://dx.doi.org/10.1158/2767-9764.CRC-23-0459

Ng CA; Luckett T; Mulhern B; Kee D; Lai-Kwon J; Joshua AM, 2024, 'What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life', Melanoma Research, 34, pp. 248 - 257, http://dx.doi.org/10.1097/CMR.0000000000000961

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', The Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF, 2024, 'Retraction Note: Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy (British Journal of Cancer, (2015), 112, 5, (832-840), 10.1038/bjc.2015.17)', British Journal of Cancer, 130, pp. 1232, http://dx.doi.org/10.1038/s41416-024-02660-4

Hiong A; O'Day R; Fog LS; McKay D; McKenzie J; Ameratunga M; Joshua AM; Shackleton M, 2024, 'Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma', Ophthalmology Retina, 8, pp. 325 - 330, http://dx.doi.org/10.1016/j.oret.2023.10.009

Zhang J; Joshua AM; Li Y; O'Meara CH; Morris MJ; Khachigian LM, 2024, 'Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma', Cancer Letters, 586, http://dx.doi.org/10.1016/j.canlet.2024.216633

Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C, 2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67, http://dx.doi.org/10.1111/bju.16190

Yu EY; Joshua AM; Kramer G; Shore ND; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.', Journal of Clinical Oncology, 42, pp. TPS249 - TPS249, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps249

Yu EY; Joshua AM; Shore ND; Kramer G; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.', Journal of Clinical Oncology, 42, pp. TPS250 - TPS250, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps250

Mellor R; Ardolino L; Scheinberg T; Fitzpatrick M; Lin HM; Bonnitcha P; Sullivan D; Meikle PJ; Stockler MR; Moujaber T; Joshua A; Horvath L, 2024, 'Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241307814

Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID; Akhurst T; Alipour R; Bailey D; Banks P; Beaulieu A; Campbell L; Crumbaker M; Dhiantravan N; Hamid A; Haskali M; Hung T; Kong G; Lawrence N; Lewin J; McCarthy M; Moodie K; Murphy D; Nguyen A; Pook D; Ravi Kumar A; Roach P; Roselt P; Saghebi J; Schembri G; Spain L; Subramaniam S; Thang SP; Thomas P; Tran B; Wallace R; Yip S, 2024, 'Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial', The Lancet Oncology, 25, pp. 99 - 107, http://dx.doi.org/10.1016/S1470-2045(23)00529-6

Wahab S; Joshua A; Dhillon HM; Barnet M, 2024, 'Psychological impact of exceptional response in people with advanced cancer: a qualitative exploration', Journal of Cancer Survivorship, http://dx.doi.org/10.1007/s11764-024-01655-7

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. S975 - S976, http://dx.doi.org/10.1016/j.annonc.2024.08.1697

Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, '676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', Annals of Oncology, 35, pp. S528 - S528, http://dx.doi.org/10.1016/j.annonc.2024.08.742

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua A; Emmett L; Murphy D; Hsiao E; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS, 2024, 'LBA66 UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)', Annals of Oncology, 35, pp. S1255 - S1256, http://dx.doi.org/10.1016/j.annonc.2024.08.2309

Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P, 2023, 'Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma', New England Journal of Medicine, 389, pp. 2256 - 2266, http://dx.doi.org/10.1056/NEJMoa2304753

Liu J; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Gaus A; Yau W; Cosman R; Chwialkowska D; Paull JRA; Jean-Francois BM; Fairley JK; Main NJ; Edmondson SR; Cook N, 2023, 'Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours', Molecular Cancer Therapeutics, 22, pp. B039 - B039, http://dx.doi.org/10.1158/1535-7163.targ-23-b039

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM, 2023, 'Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial', Clinical Cancer Research, 29, pp. 3867 - 3874, http://dx.doi.org/10.1158/1078-0432.CCR-23-0731

Ardolino LC; Dear R; Armstrong AJ; Gillessen S; Joshua AM, 2023, 'Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4–6', European Urology, 84, pp. e94 - e95, http://dx.doi.org/10.1016/j.eururo.2023.04.043

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H, 2023, 'A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer', Clinical Cancer Research, 29, pp. 3292 - 3300, http://dx.doi.org/10.1158/1078-0432.CCR-22-2585

Back to profile page